BioCentury
ARTICLE | Clinical News

HepaSphere Microspheres regulatory update

December 24, 2007 8:00 AM UTC

BSMD received CE Mark approval in the EU for use of its HepaSphere Microspheres to deliver doxorubicin in transarterial chemoembolization procedures to treat hepatocellular carcinoma. As a condition o...